ReviewFrontiers in pharmacology2026
The gut-brain axis in pharmacology: microbiome-driven modulation of CNS drugs and neuropsychiatric outcomes.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gut-brain axis has emerged as a critical regulator of Central Nervous System (CNS) pharmacology, significantly influencing drug response and neuropsychiatric outcomes through complex interactions between the gut microbiota and host systems. Objective: This review aims to examine the role of gut microbiota in modulating the pharmacokinetics and pharmacodynamics of CNS drugs, and to explore their implications in neuropsychiatric disorders. Key findings: Accumulating evidence indicates that microbial enzymes and metabolites can alter drug absorption, metabolism, and bioavailability, particularly for antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs). In turn, psychotropic medications can modify gut microbial composition, leading to dysbiosis and variability in therapeutic outcomes. Microbiota-derived metabolites, immune signaling pathways, and host genetic factors (e.g., cytochrome P450 polymorphisms) collectively contribute to interindividual differences in drug efficacy and safety. Conclusion: Integration of microbiome profiling into pharmacological research holds significant potential for advancing precision medicine in neuropsychiatry. However, challenges such as methodological heterogeneity, limited longitudinal clinical data, and lack of standardized biomarkers must be addressed to enable clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.